港股异动|复星医药涨逾4%旗下新药获准于台湾进行临床试验
格隆汇7月15日丨复星医药(2196.HK)现报24.85港元,涨4.19%,暂成交3760万港元,最新总市值636.88亿港元。复星医药上周五(12日)发布公告称,子公司汉霖生技收到台湾卫生福利部关于同意HLX10(重组抗PD-1人源化单克隆抗体注射液)用于慢性B型肝炎(即慢性乙型肝炎)治疗进行临床试验。汉霖生技拟于近期条件具备后于台湾开展针对该适应症的临床II期试验。据悉,该新药为公司自主研发的创新型治疗用生物制品,主要用于实体瘤治疗,目前正进一步探索慢性B型肝炎治疗的可能性。此外,复宏汉霖拟发行境外上市外资股获证监会核准。复星医药将于下周三(24日)除权,拟派息每股0.36港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.